LAG3 inhibition for treating metastatic or unresectable melanoma has a reduced efficacy in patients with type 2 diabetes, possibly due to a low expression of LAG3 in tumor tissue. The gene discussed is LAG3; the disease is type 2 diabetes mellitus.